GLPG-0634isatriazolopyridinethatinhibitsJAK1;itexhibitsanti-inflammatoryandimmunomodulatoryactivities.GLPG-0634preventsreleaseofinflammatorycytokinesandiscurrentlyunderinvestigationasapotentialtreatmentforrheumatoidarthritisandCrohn’sdisease.
| CasNo. | 1206161-97-8 |
|---|---|
| Purity | ≥98% |
| Formula | C21H23N5O3S |
| FormulaWt. | 425.50 |
| IUPACName | N-(5-{4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide |
| Synonym | GLPG0634,Filgotinib |
| Appearance | WhiteCrystalPowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | G4662InfoSheetPDF |
|---|
NamourF,DiderichsenPM,CoxE,etal.PharmacokineticsandPharmacokinetic/PharmacodynamicModelingofFilgotinib(GLPG0634),aSelectiveJAK1Inhibitor,inSupportofPhaseIIBDoseSelection.ClinPharmacokinet.2015Feb14.[Epubaheadofprint].PMID:25681059.
MenetCJ,FletcherSR,VanLommenG,etal.TriazolopyridinesasselectiveJAK1inhibitors:fromhitidentificationtoGLPG0634.JMedChem.2014Nov26;57(22):9323-42.PMID:25369270.
NormanP.SelectiveJAKinhibitorsindevelopmentforrheumatoidarthritis.ExpertOpinInvestigDrugs.2014Aug;23(8):1067-77.PMID:24818516.
